Revelation Biosciences Lead Product Tested For SARS-CoV-2 Treatment

Revelation Biosciences announced that it has observed a serious decrease in the viral load with the use of its lead product candidate, REVTx99, in three independent in vitro cell-based assays for the treatment of SARS-CoV-2 infections. In connection with the purchase of Petra Acquisition, Inc., the company has been trading on the market with “REV” name since January 11. REVTx99 is a novel drug candidate that activates the toll-like receptor 4 (TLR4), which is a key component of the host’s response to infection.

Revelation Biosciences

Revelation Biosciences’ lead product candidate was tested for its ability to prevent infection with SARS-CoV-2 Delta by inactivating the TLR4 and ACEII receptors. A human bronchial/tracheal cell was treated with 250 nanograms per mL of REVTx99 for one hour before infection. The viral load was then decreased by more than 50%. Through in vitro and in vivo studies, the company is developing a strategy to identify a dose range that can maximize the anti-viral effects of REVTx99 against different strains of SARS-CoV-2.

Anthony Gonzales

Biotech, Tech, and Crypto reporter Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.

Anthony Gonzales has 1700 posts and counting. See all posts by Anthony Gonzales